The Prange Group and its affiliate Adragos Pharma have successfully acquired the Fresenius Kabi production site in Halden, Norway, a leading sterile pharmaceutical manufacturing facility. This strategic move signifies a significant step forward for both companies, expanding their global footprint and enhancing their capacity for sterile liquid production.
The Halden site, strategically located in Norway, boasts advanced capabilities for sterile liquid production, including IV bags, blow-fill-seal technology for ampoules and vials, and compounding activities for the local market. Formerly a key asset of Fresenius Kabi, the site has served as a contract manufacturer for various pharmaceutical giants, supplying products to over 70 countries worldwide.
The Prange Group, a reputable German family business with a strong track record in pharmaceutical investments, views this acquisition as an opportunity to further develop the Halden site and strengthen its position in the industry. Otto Prange, Chairman and Owner of the Prange Group, expresses gratitude to Fresenius Kabi for their trust and emphasizes their commitment to ensuring reliable global supply for customers.
Dr. Andreas Raabe, CEO of Adragos Pharma, highlights the strategic alignment between Adragos Pharma and the Prange Group, aiming to deliver quality and reliability on a global scale. This acquisition is expected to unlock new potential, leveraging the expertise of the workforce and fostering growth and innovation.
While the detailed terms of the transaction remain undisclosed, both parties are optimistic about the future prospects of the Halden site under the new ownership.